Profile: Lexicon Pharmaceuticals Inc (LXRX.O)
23 May 2013
Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals), incorporated in July 1995, is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon Pharmaceuticals uses its gene knockout technologies and an integrated platform of medical technologies to study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as drug targets. It has five drug programs in various stages of clinical development and has advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research. Its drug program includes LX4211, LX1032, LX1033, LX2931 and LX7101.
LX4211 is an orally delivered small molecule compound, which is being developed for the treatment of type diabetes mellitus. The Phase IIb trial has enrolled 299 patients with type II diabetes who are not controlled on metformin monotherapy in a double-blind, randomized, placebo-controlled study of 75milligrams once daily, 200 milligrams once daily, 200 milligrams twice daily and 400 milligrams once daily doses of LX4211, each administered in combination with standard metformin therapy over a 12week treatment period. LX4211 was internally generated by its medicinal chemists and inhibits both sodium-glucose cotransporter type II (SGLT2), a transporter responsible for most of the glucose reabsorption performed by the kidney, and sodium-glucose cotransporter type I (SGLT1), a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney.
LX1032 (Telotristat etiprate)
LX1032 is an orally delivered small molecule compound that the Company is developing for the treatment of symptoms associated with carcinoid syndrome and is preparing for the initiation of pivotal Phase III clinical trials. The Phase II trial enrolled 23 patients with symptomatic carcinoid syndrome who were refractory to octreotride therapy in a double-blind, randomized, placebo-controlled study of 150 milligrams, 250 milligrams, 350 milligrams and 500 milligrams doses of telotristat etiprate, each administered three times daily over a 28-day treatment period in combination with octreotide therapy. In addition to carcinoid syndrome, it is also developing telotristat etiprate for the potential treatment of ulcerative colitis and initiated a Phase II clinical trial in February 2012.
LX1033 is an orally delivered small molecule compound that the Company is developing for the treatment of irritable bowel syndrome. It initiated a Phase II clinical trial in February 2012 to evaluate the safety and tolerability of LX1033 and symptoms associated with irritable bowel syndrome. LX1033 was internally generated by its medicinal chemists as an inhibitor of TPH, the same target as telotristat etiprate, but LX1033 is chemically distinct and was designed to reduce production of serotonin in the gastrointestinal tract. In preclinical studies, LX1033 demonstrated dose-dependent reductions of serotonin levels in the gastrointestinal tract of multiple species without affecting brain serotonin levels.
LX2931 is an orally delivered small molecule compound that we are developing for the treatment of autoimmune diseases, such as rheumatoid arthritis. The Phase II trial enrolled 208 patients with rheumatoid arthritis who were also taking methotrexate, a standard therapy, in a double-blind, randomized, placebo-controlled study of 70 milligrams, 110 milligrams and 150 milligrams doses of LX2931, each administered once daily over a 12-week treatment period. In these Phase I studies, LX2931 demonstrated a dose-dependent reduction in circulating lymphocytes. LX2931 was internally generated by its medicinal chemists to target sphingosine-1-phosphate lyase (S1P) lyase, an enzyme in the S1P pathway associated with the activity of lymphocytes.
X7101 is a topically-delivered small molecule compound that the Company is developing for the treatment of glaucoma. LX7101 was internally generated by its medicinal chemists to target LIMK2, a kinase associated with the regulation of intraocular pressure, and is designed to lower intraocular pressure by enhancing the fluid outflow facility of the eye.
Lexicon Pharmaceuticals Inc
8800 Technology Forest Place
THE WOODLANDS TX 77381-1160